33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4873)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15823)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7078)
  4. Hematologic Malignancies, Division of (6211)
  5. Center for Hematologic Malignancies (6018)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL)
    Meeting Abstract

    Grommes, C.; Tun, H. W.; de la Fuente Burguera, A. D.; Dabrowska-Iwanicka, A.; Regales, L.; Zhao, W.; Ferrari, D.; Fowles, M.; Lane, M. E.; Wang, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)
    Meeting Abstract

    Lim, K. H.; Spencer, K. R.; Safyan, R. A.; Picozzi, V. J.; Varghese, A. M.; Siolas, D.; Perez, K.; Clift, S.; Denis, L. J.; Bhambhani, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety outcomes in patients with acute myeloid leukemia receiving gemtuzumab ozogamicin and proceeding to allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Kebriaei, P.; Ho, V.; Perales, M. A.; Bejanyan, N.; Kaur, M.; Zhang, M. J.; D'Amico, P. G.; Purcell, S.; Dorman, S.; Vandendries, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease-positive pancreatic and colorectal cancer
    Meeting Abstract

    Devoe, C. E.; Pant, S.; Wainberg, Z. A.; Chung, V.; George, T. J.; Kasi, P. M.; VanWyk, H.; Tavares, A.; Perry, J.; Kheoh, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results
    Meeting Abstract

    Segal, N. H.; Girda, E.; Sohal, D.; Lakhani, N. J.; Olszanski, A. J.; Fong, L.; Kinnaman, M. D.; Han, H.; Skokos, D.; Casey, K. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T)
    Meeting Abstract

    Bock, A. M.; Raj, S.; Giri, S.; Leslie, L. A.; Patel, D. A.; Iqbal, M.; Grover, N. S.; Hu, B.; Perales, M. A.; Nowakowski, G. S.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial
    Meeting Abstract

    Reinmuth, N.; Mazieres, J.; Popat, S.; Paz-Ares, L. G.; Hook, E. S.; Hatswell, A.; Vlassak, S.; Johne, A.; Vioix, H.; Paik, P. K.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HLA associations with immunotherapy related endocrine toxicity
    Meeting Abstract

    Quandt, Z.; Thorball, C.; Middha, P.; Johnson, D. B.; Bejan, C. A.; Yao, L.; Xu, Y.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry
    Meeting Abstract

    Luo, J.; Kim, J. J.; Walton, S. A.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; Hsu, R.; Piha-Paul, S. A.; Janne, P. A.; Sholl, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT
    Meeting Abstract

    Bejanyan, N.; Ho, V.; Perales, M. A.; Kebriaei, P.; Kaur, M.; Zhang, M. J.; D'Amico, P. G.; Purcell, S.; Dorman, S.; Vandendries, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save